-
- Comment in:
-
N Engl J Med. 2005 Dec 22;353(25):2633-6.
-
N Engl J Med. 2006 Mar 30;354(13):1423-4; author reply 1423-4.
Oseltamivir resistance during treatment of influenza A (H5N1) infection.
de Jong MD,
Tran TT,
Truong HK,
Vo MH,
Smith GJ,
Nguyen VC,
Bach VC,
Phan TQ,
Do QH,
Guan Y,
Peiris JS,
Tran TH,
Farrar J.
Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam. mddejong@hcm.vnn.vn
Influenza A (H5N1) virus with an amino acid substitution in neuraminidase conferring high-level resistance to oseltamivir was isolated from two of eight Vietnamese patients during oseltamivir treatment. Both patients died of influenza A (H5N1) virus infection, despite early initiation of treatment in one patient. Surviving patients had rapid declines in the viral load to undetectable levels during treatment. These observations suggest that resistance can emerge during the currently recommended regimen of oseltamivir therapy and may be associated with clinical deterioration and that the strategy for the treatment of influenza A (H5N1) virus infection should include additional antiviral agents. Copyright 2005 Massachusetts Medical Society.
PMID: 16371632 [PubMed - indexed for MEDLINE]
-
Cited by 53 PubMed Central articles
-
What is the optimal therapy for patients with H5N1 influenza?
White NJ, Webster RG, Govorkova EA, Uyeki TM.
PLoS Med. 2009 Jun 23; 6(6):e1000091. Epub 2009 Jun 23.
[PLoS Med. 2009]
-
Identification and characterisation of a novel anti-viral peptide against avian influenza virus H9N2.
Rajik M, Jahanshiri F, Omar AR, Ideris A, Hassan SS, Yusoff K.
Virol J. 2009 Jun 5; 6:74. Epub 2009 Jun 5.
[Virol J. 2009]
-
Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses.
Sun L, Lu X, Li C, Wang M, Liu Q, Li Z, Hu X, Li J, Liu F, Li Q, et al.
PLoS One. 2009; 4(5):e5476. Epub 2009 May 7.
[PLoS One. 2009]
- » See all...